Abnormal fragile histidine triad (FHIT) expression in advanced cervical carcinoma: A poor prognostic factor

Cancer Research

Volumn 61, Issue 11, 2001, Pages 4382-4385

  Krivak, Thomas C ^a   McBroom, John W ^a   Seidman, Jeffrey ^b   Venzon, David ^c   Crothers, Barbara ^a   MacKoul, Paul J ^b   Rose, G Scott ^a   Carlson, Jay W ^a   Birrer, Michael J ^c  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN; HISTIDINE;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CARCINOMA;

ACID ANHYDRIDE HYDROLASES; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN BIOSYNTHESIS; PROTEINS; RISK FACTORS; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS;

EID: 0035360834     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Cancer statistics
2. Uterine cervix
3. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
4. Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products
5. Allelotype of uterine cancer by analysis of RFLP and microsatellite polymorphisms: Frequent loss of heterozygosity on chromosome arms 3p, 9q, 10q, and 17p
6. Loss of heterozygosity on the short arm of chromosome 3 in carcinoma of the uterine cervix
7. Deletions of chromosome 3p are frequent and early events in the pathogenesis of uterine cervical carcinoma
8. High resolution analysis of chromosome 3p alterations in cervical carcinoma
9. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers
10. FHITness and cancer
11. Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions
12. FHIT gene expression in human ovarian, endometrial, and cervical cancer cell lines
13. Abnormal Fhit expression in malignant and premalignant lesions of the cervix
14. Loss of fhit expression in invasive cervical carcinomas and intraepithelial lesions associated with invasive disease
15. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors
16. A possible involvement of aberrant expression of the FHIT gene in the carcinogenesis of squamous cell carcinoma of the uterine cervix
17. Aberrant FHIT transcripts in squamous cell carcinoma of the uterine cervix
18. FHIT alterations in cancerous and non-cancerous cervical epithelium
19. Fhit expression in gastric adenocarcinoma: Correlation with disease stage and survival
20. FHIT gene in gastric cancer: Association with tumour progression and prognosis
21. Clinicopathological significance of Fhit protein expression in stage I non-small cell lung carcinoma
22. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer
23. The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma
24. Clinicopathological significance of fragile histidine triad transcription protein expression in endometrial carcinomas
25. Expression of FHIT in primary cultures of human epithelial ovarian tumors and malignant ovarian ascites
26. Primary cervical carcinomas show 2 common regions of deletion at 3P, 1 within the FHIT gene: Evaluation of allelic imbalance at FHIT, RBI and TP53 in relation to survival
27. Protein expression and functional analysis of the FHIT gene in human tumor cells
28. Restored expression of fragile histidine triad protein and tumorigenicity of cervical carcinoma cells
29. The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control
30. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression